These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15552798)

  • 21. Receptor-mediated mitogenic signals and lung cancer.
    Schüller HM
    Cancer Cells; 1991 Dec; 3(12):496-503. PubMed ID: 1668140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P2 receptors and cancer.
    White N; Burnstock G
    Trends Pharmacol Sci; 2006 Apr; 27(4):211-7. PubMed ID: 16530853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular networks in respiratory epithelium carcinomas.
    Pallis AG; Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Cancer Lett; 2010 Sep; 295(1):1-6. PubMed ID: 20381956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Other compounds and targets in non-small cell lung cancer.
    Villaflor V; Bonomi P
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S30-6. PubMed ID: 16459177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy.
    Shen HM; Tergaonkar V
    Apoptosis; 2009 Apr; 14(4):348-63. PubMed ID: 19212815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of therapy-induced autophagy and necrosis in cancer treatment.
    Amaravadi RK; Thompson CB
    Clin Cancer Res; 2007 Dec; 13(24):7271-9. PubMed ID: 18094407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to develop a successful cancer drug--molecules to medicines or targets to treatments?
    Newell DR
    Eur J Cancer; 2005 Mar; 41(5):676-82. PubMed ID: 15763642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel targets for lung cancer therapy: part I.
    Dy GK; Adjei AA
    J Clin Oncol; 2002 Jun; 20(12):2881-94. PubMed ID: 12065566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway.
    Lee YJ; Imsumran A; Park MY; Kwon SY; Yoon HI; Lee JH; Yoo CG; Kim YW; Han SK; Shim YS; Piao W; Yamamoto H; Adachi Y; Carbone DP; Lee CT
    Lung Cancer; 2007 Mar; 55(3):279-86. PubMed ID: 17134788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy for non-small cell lung cancer.
    Toloza EM; D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New targeted treatments in lung cancer--overview of clinical trials.
    Korfee S; Gauler T; Hepp R; Pöttgen C; Eberhardt W
    Lung Cancer; 2004 Aug; 45 Suppl 2():S199-208. PubMed ID: 15552800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developmental signalling pathways in lung cancer.
    Daniel VC; Peacock CD; Watkins DN
    Respirology; 2006 May; 11(3):234-40. PubMed ID: 16635080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.